Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UBT251 Pharmacokinetics Study in Overweight or Obesity
NCT07710768Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Jul 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of UBT251 in obesity (2 arms), sponsored by Novo Nordisk. Primary endpoints: Area Under the Plasma s-warfarin Concentration-time Curve Extrapolated to Infinity at 156 days, Area Under the Plasma Caffeine Concentration-time Curve Extrapolated to Infinity at 156 days and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
UBT251
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07710768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07710768.